Clinical evaluation of the Hydra self-expanding transcatheter aortic valve: 6 month results from the GENESIS trial.
Praveen ChandraJohn JoseShafeeq MattummalAjaykumar U MahajanSajeev C GovindanChandrashekhar N MakhaleSharad ChandraRanjan ShettySandeep MohananJohn F JohnSanjay MehrotraLars SøndergaardPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2021)
The GENESIS trial demonstrated high efficacy of the self-expanding Hydra THV. The cardiovascular mortality rate of 7.5% may partly be explained by the inclusion of some centres with no or limited previous experience in transcatheter aortic valve implantation.
Keyphrases
- aortic valve
- transcatheter aortic valve implantation
- aortic valve replacement
- clinical evaluation
- aortic stenosis
- transcatheter aortic valve replacement
- phase iii
- study protocol
- phase ii
- clinical trial
- randomized controlled trial
- risk factors
- cardiovascular events
- open label
- cardiovascular disease
- left ventricular
- heart failure
- type diabetes
- atrial fibrillation